KRSNAA DIAGNOSTICS LTD
Latest filings
Next results: Mon, 2 Nov · Financial Results- Krsnaa Diagnostics schedules Q2 and H1 FY27 earnings call · Board & Shareholder Meetings
- Board meeting set for November 2 to approve quarterly results · Results
- Krsnaa Diagnostics collaborates with AZmed on artificial intelligence radiology · Strategic Transactions
Snapshot
What the business is, and whether it's a good one at a fair price.
Runs a nationwide diagnostic services network under public-private partnership (PPP) contracts with state governments, alongside a growing retail diagnostics brand. Operates 190+ CT/MRI centers, 147 pathology labs and 4,700+ patient collection centers across 18 states, processing 59 million tests and serving 20 million patients in FY26. The PPP arm — including a Rajasthan project with 27 mother labs and 800+ collection centers, and a new 7-year Himachal Pradesh contract covering CT scans at 34 government health institutions — supplies the bulk of revenue, with FY27 capex of ₹500 crore earmarked for further expansion (₹300+ crore Rajasthan, ₹150+ crore MRI). The retail arm operates 3,500+ touchpoints across 5 states with 54 NABL-accredited labs and 54 NABH-accredited radiology centers, contributing ~8% of FY26 revenue at ~₹60 crore. Costs split as materials (23.2% of revenue), employees (18.2%), other opex (31.2%) and depreciation (11.7%); FY26 capex ran at 28.4% of revenue. Days sales outstanding stood at 139 days at year-end versus 155 days earlier, with a sub-120 day FY27 target.
Scorecard
Measured from the filed financials, judged against its Healthcare Service Provider peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from KRSNAA DIAGNOSTICS LTD's filed financials and exchange disclosures
What does KRSNAA DIAGNOSTICS LTD do?
KRSNAA DIAGNOSTICS LTD is a Healthcare Services company listed on NSE and BSE, trading under the symbol KRSNAA.
Is KRSNAA DIAGNOSTICS LTD profitable?
Yes. Over the trailing twelve months KRSNAA DIAGNOSTICS LTD reported a net profit of ₹97 Cr on revenue of ₹815 Cr.
Does KRSNAA DIAGNOSTICS LTD pay a dividend?
Yes. The dividend yield is 0.55% at the current price. It paid out 9% of its profit as dividend in FY26.
Is KRSNAA DIAGNOSTICS LTD debt-free?
No. It reported borrowings of ₹534 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹504 Cr after cash. Debt stands at 0.55× equity. That is higher than 82% of its 23 Healthcare Service Provider peers.
Is KRSNAA DIAGNOSTICS LTD expensive compared with its peers?
On trailing P/E, KRSNAA DIAGNOSTICS LTD ranks 8 of 25 in Healthcare Service Provider — cheaper than 71% of them, against an industry median of 23.6×. This is a position, not a valuation judgement.
How much does the KRSNAA DIAGNOSTICS LTD share price move in a day?
On a typical session KRSNAA DIAGNOSTICS LTD moves 1.19% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
When are KRSNAA DIAGNOSTICS LTD's next results?
Financial Results on Mon, 2 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track KRSNAA DIAGNOSTICS LTD's announcements?
Every NSE and BSE filing by KRSNAA DIAGNOSTICS LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.